Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Other Non-Current Liabilities (2020 - 2023)

Historic Other Non-Current Liabilities for Evoke Pharma (EVOK) over the last 4 years, with Q4 2023 value amounting to $1.6 million.

  • Evoke Pharma's Other Non-Current Liabilities rose 4495.21% to $1.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.6 million, marking a year-over-year increase of 4495.21%. This contributed to the annual value of $1.6 million for FY2023, which is 4495.21% up from last year.
  • Evoke Pharma's Other Non-Current Liabilities amounted to $1.6 million in Q4 2023, which was up 4495.21% from $1.5 million recorded in Q3 2023.
  • Evoke Pharma's 5-year Other Non-Current Liabilities high stood at $1.6 million for Q4 2023, and its period low was -$1.4 million during Q2 2023.
  • Moreover, its 4-year median value for Other Non-Current Liabilities was $673939.0 (2021), whereas its average is $609191.2.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 81740.02% in 2021, then crashed by 25812.33% in 2023.
  • Evoke Pharma's Other Non-Current Liabilities (Quarter) stood at $112994.0 in 2020, then surged by 441.88% to $612295.0 in 2021, then surged by 81.66% to $1.1 million in 2022, then surged by 44.95% to $1.6 million in 2023.
  • Its Other Non-Current Liabilities was $1.6 million in Q4 2023, compared to $1.5 million in Q3 2023 and -$1.4 million in Q2 2023.